Lee Jina, Pai Hyunjoo, Kim Yun Kyung, Kim Nam Hee, Eun Byung Wook, Kang Hyoung Jin, Park Kyoung Ho, Choi Eun Hwa, Shin Hee Young, Kim Eui Chong, Lee Hoan Jong, Ahn Hyo Seop
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
J Antimicrob Chemother. 2007 Sep;60(3):629-37. doi: 10.1093/jac/dkm225. Epub 2007 Jun 27.
This ambidirectional intervention study was performed to examine the impact of a change in antibiotic policy on extended-spectrum beta-lactamase (ESBL) prevalence in a children's hospital with a high prevalence of ESBL production among Escherichia coli and Klebsiella pneumoniae.
The use of extended-spectrum cephalosporins was restricted and use of beta-lactam/ beta-lactamase inhibitor combinations was encouraged from 2002. All strains of E. coli and K. pneumoniae isolated from sterile body fluids from 1999 to 2005 were analysed for beta-lactamase production and the prevalences of ESBL production were compared at three periods; pre-intervention (1999-2001), transitional period (2002-03) and post-intervention (2004-05).
Comparing the pre- and post-intervention periods, overall piperacillin/tazobactam use increased from 2.2 to 108.0 days on antibiotics/1000 patient admission days/year (AD) (P for trend < 0.001), whereas extended-spectrum cephalosporin use decreased from 175.0 to 96.9 AD (P for trend < 0.001). Among 252 strains of E. coli (n = 128) and K. pneumoniae (n = 124), the overall prevalence of ESBL producers decreased from 39.8% (41/103) to 22.8% (18/79) (P for trend = 0.018). This decreasing trend of ESBL production was more evident for K. pneumoniae (64.1% to 25.6%; P for trend < 0.001) than E. coli (25.0% to 19.4%; P for trend = 0.514). The mortality rates of invasive disease caused by E. coli or K. pneumoniae remained unchanged.
The substitution of piperacillin/tazobactam for extended-spectrum cephalosporins successfully decreased the prevalence of ESBL production of K. pneumoniae and E. coli in an institute for children where ESBLs were endemic. The impact of change in antibiotic policy was more evident in K. pneumoniae than E. coli.
本双向干预研究旨在考察抗生素政策的改变对一家儿童医院超广谱β-内酰胺酶(ESBL)流行率的影响,该医院大肠埃希菌和肺炎克雷伯菌中产ESBL的情况很普遍。
自2002年起,限制使用超广谱头孢菌素,并鼓励使用β-内酰胺/β-内酰胺酶抑制剂联合制剂。对1999年至2005年从无菌体液中分离出的所有大肠埃希菌和肺炎克雷伯菌菌株进行β-内酰胺酶产生情况分析,并比较三个时期ESBL产生的流行率;干预前(1999 - 2001年)、过渡期(2002 - 2003年)和干预后(2004 - 2005年)。
比较干预前后时期,哌拉西林/他唑巴坦的总体使用量从2.2天/1000患者入院日/年增加至108.0天/1000患者入院日/年(趋势P<0.001),而超广谱头孢菌素的使用量从175.0天/1000患者入院日降至96.9天/1000患者入院日(趋势P<0.001)。在252株大肠埃希菌(n = 128)和肺炎克雷伯菌(n = 124)中,产ESBL菌株的总体流行率从39.8%(41/103)降至22.8%(18/79)(趋势P = 0.018)。肺炎克雷伯菌产ESBL的下降趋势(从64.1%降至25.6%;趋势P<0.001)比大肠埃希菌(从25.0%降至19.4%;趋势P = 0.514)更明显。由大肠埃希菌或肺炎克雷伯菌引起的侵袭性疾病的死亡率保持不变。
在ESBL流行的儿童医院,用哌拉西林/他唑巴坦替代超广谱头孢菌素成功降低了肺炎克雷伯菌和大肠埃希菌产ESBL的流行率。抗生素政策改变对肺炎克雷伯菌的影响比对大肠埃希菌更明显。